 |
|
|
| |
Durable Efficacy of Switching From a 3-/4-Drug Tenofovir Alafenamide (TAF)-Based Regimen to the 2-Drug Regimen
Dolutegravir/Lamivudine (DTG/3TC) in the TANGO Study Through Week 196
|
| |
| |
HIV Drug Therapy Glasgow; October 23-26, 2022; Virtual and Glasgow, Scotland
Stéphane De Wit,1 Fabrice Bonnet,2 Olayemi Osiyemi,3 Fiona Bisshop,4 Julian Olalla,5 Jean-Pierre Routy,6 Christoph Wyen,7 Riya Moodley,8 Keith Pappa,9 Ruolan Wang,9 James Oyee,10 Parminder Saggu,10
Emilio Letang,11 Brian Wynne,9 Bryn Jones,8 Kimberly Y. Smith,9 Mounir Ait-Khaled8
1CHU Saint-Pierre, Université Libre de Bruxelles, Brussels, Belgium; 2CHU de Bordeaux, Service de Médecine Interne et Maladies Infectieuses, Bordeaux, France; 3Triple O Research Institute PA, West Palm Beach, FL, USA; 4Holdsworth House Medical Brisbane, Queensland, Australia; 5Unidad de Medicina Interna, Hospital Costa del Sol, Marbella, Spain; 6McGill University Health Centre, Montreal, QC, Canada; 7Praxis am Ebertplatz, Cologne, Germany; 8ViiV Healthcare, Brentford, UK; 9ViiV Healthcare, Durham, NC, USA;
10GSK, Brentford, UK; 11ViiV Healthcare, Madrid, Spain
|
| |
|
|
|
|
|
